Inhibiting Gal3 may reduce chronic inflammation and balance phagocytosis/endocytosis without hampering the expression of TREM2 and Clec7a which are thought to have a positive effect in some diseases such as AD (Wang et al., 2022). Here, CLEC7A is linked to Alzheimer disease.